2247 GMT - Monash IVF's share-price fall following this week's profit warning leaves the company more vulnerable to a bid. Jefferies says reasons for Monash IVF lowering FY 2025 profit guidance to some A$27.5 million likely include the discretionary nature of IVF treatment as well as Monash IVF's exposure to Victoria, a state that is facing economic challenges. "We do not expect a sudden turnaround in IVF volumes but highlight there may be corporate interest in IVF if an acquirer is willing to take a longer-term view given favorable industry dynamics," analyst David Stanton says. Monash IVF's shares are down around 47% over the past 12 months. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
May 21, 2025 18:47 ET (22:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.